Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 11/20 | 0.47 |
| ▸ | EGFR | P00533 | 10/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17075842 | 0.94 | ERBB2 (0.47) | ERBB2EGFRNPC1ALDH1A1TSHR | |
| SCHEMBL17075823 | 0.89 | ERBB2 (0.48) | ERBB2EGFRNPC1ALDH1A1TSHR | |
| SCHEMBL17075903 | 0.87 | ERBB2 (0.46) | ERBB2EGFRNPC1ALDH1A1TSHR | |
| SCHEMBL17075833 | 0.85 | ERBB2 (0.46) | ERBB2EGFRNPC1ALDH1A1TSHR | |
| SCHEMBL17075803 | 0.85 | ERBB2 (0.48) | ERBB2EGFRNPC1ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL17075893 | 0.85 | EGFR (0.58) | ERBB2EGFR | |
| SCHEMBL17075824 | 0.83 | EGFR (0.54) | ERBB2EGFR | |
| SCHEMBL17075838 | 0.82 | ERBB2 (0.52) | ERBB2EGFRNPC1ALDH1A1TSHR | |
| SCHEMBL17075817 | 0.81 | EGFR (0.52) | ERBB2EGFR | |
| SCHEMBL17075848 | 0.80 | ERBB2 (0.52) | ERBB2EGFRNPC1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150259331-A1 | PROTOZOAN PARASITE GROWTH INHIBITORS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150259331-A1 | PROTOZOAN PARASITE GROWTH INHIBITORS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259331-A1 | PROTOZOAN PARASITE GROWTH INHIBITORS | TPP1, MKI67, PIGO | ERBB2 4468/4885EGFR 4389/4885NPC1 2371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.